
Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.
Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses an analysis of chemotherapy administration and survival in soft tissue sarcoma.
Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses an analysis of






